Related Experiment Video

Updated: Jul 18, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

The economics of hepatitis C virus

Bhavesh B Shah1, John B Wong

  • 1Division of Clinical Decision Making, Informatics, and Telemedicine, Tufts-New England Medical Center, Tufts University School of Medicine, 750 Washington Street #302, Boston, MA 02111, USA.

Clinics in Liver Disease
|December 14, 2006
PubMed

Insights

Hepatitis C virus presents a significant global health challenge, impacting morbidity, mortality, and healthcare costs. This article examines the economic burden of hepatitis C, including therapy, prevention, and screening.

Area of Science:

  • Hepatology
  • Public Health
  • Health Economics

Background:

  • Hepatitis C virus (HCV) infection is a major global health concern.
  • It leads to significant morbidity, mortality, and substantial economic consequences.
  • The full global economic burden of HCV remains underestimated.

Purpose of the Study:

  • To analyze the economic burden associated with hepatitis C.
  • To evaluate the economics of hepatitis C treatment.
  • To assess the economic aspects of hepatitis C prevention and screening strategies.

Main Methods:

  • Review of existing literature on the economic impact of hepatitis C.
  • Analysis of cost-effectiveness data for hepatitis C therapies.
  • Examination of economic models for hepatitis C prevention and screening programs.

Main Results:

  • Hepatitis C imposes a considerable economic burden globally.
  • Therapeutic interventions for hepatitis C have significant associated costs.
  • Prevention and screening initiatives also represent substantial economic considerations.

Conclusions:

  • Understanding the economic dimensions of hepatitis C is crucial for public health policy.
  • Cost-effective strategies for therapy, prevention, and screening are essential.
  • Further research is needed to fully quantify the global economic impact of hepatitis C.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...